Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab in Severe COVID-19 (BEST-CP)
NCT04275414Phase 2Completed
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Feb 2020
- Primary completion
- Apr 2020
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in coronavirus disease 2019 (COVID-19), sponsored by Qilu Hospital of Shandong University. Primary endpoint: Partial arterial oxygen pressure (PaO2) to fraction of inspiration O2 (FiO2) ratio at 7 days. Started Feb 2020; status: completed.
02
Drugs
bevacizumab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04275414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04275414.